Rockwell Medical – About the Company
As an established manufacturer and leader in delivering high-quality hemodialysis concentrates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products used to maintain human life, removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream.
The Company is currently developing unique, proprietary renal drug therapies. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience and outcome.
Soluble Ferric Pyrophosphate (SFP), the Company’s lead investigational drug, is a novel iron salt capable of delivering iron in a physiological manner, providing continuous-iron-maintenance therapy for the treatment or prevention of iron deficiency anemia in dialysis patients.
Unlike current IV iron treatment used in dialysis, SFP travels directly to the bloodstream and transfers its iron load at a cellular level, similar to normal dietary iron uptake. SFP is currently progressing through U.S. clinical development and has received patent protection in several countries including in the three largest ESRD markets in the world: the U.S., Japan and Europe. Rockwell recently released positive Phase III data from one of two clinical trials, putting the company on the path for an NDA filing next year.
Rockwell is further developing new drug opportunities in the areas of women’s health, oncology, gastroenterology and parenteral nutrition based on the SFP platform, as well as new drugs for other targeted renal therapies and indications.
- Initiation of Coverage Report
- Ferric Citrate Label and Triferic 9-18-14
- Long Term Safety Data 2-7-14
- ASN Kidney Week 11-14-2013
- CRUISE 2 Data 9-5-13
- CRUISE 1 Data 7-11-13
- CRUISE Update 6-4-13
- Financing Update 5-21-13
- PRIME Data 2-13-13
- Company Update 9-20-12
- Fresensius Granuflo 6-18-12
- CRUISE DSMB 12-12-11
- VitD Valuation 10-31-11
- VitD Acquisition 7-26-11
- SFP Valuation 5-4-11
- PRIME Start 2-17-11
- ASN Note 11-21-10
- CRUISE Note 10-20-10